BioCentury | Feb 18, 2013
Finance

Wanted: Platform plays

...which Affymetrix Inc. (NASDAQ:AFFX) acquired in 2008 for about $73 million; and cancer company Miikana Therapeutics Inc....
BioCentury | May 19, 2008
Clinical News

ENMD-2076: Phase I ongoing

...triggered a $2 million milestone payment, paid in EntreMed stock to the former shareholders of Miikana...
BioCentury | Apr 14, 2008
Clinical News

ENMD-2076: Phase I started

...a $2 million milestone payment payable in cash or stock to the former stockholders of Miikana...
BioCentury | Sep 17, 2007
Clinical News

MKC-1: Interim Phase II data

...recommended continuation of the study without any modifications. ENMD gained MKC-1 through its acquisition of Miikana Therapeutics Inc....
BioCentury | Sep 11, 2007
Clinical News

EntreMed reports Phase II breast cancer data

...study without any modifications. ENMD gained the oral cell cycle inhibitor through its acquisition of Miikana...
BioCentury | Jan 29, 2007
Clinical News

MKC-1: Phase II ongoing

...to 60 patients advanced or metastatic breast cancer. ENMD gained MKC-1 through its acquisition of Miikana Therapeutics Inc....
BioCentury | Feb 6, 2006
Finance

Ebb & Flow

...seek FDA approval for their products this year. Buy & raise When EntreMed (ENMD) acquired Miikana...
...with most of the proceeds earmarked for clinical development. "Between our own pipeline and the Miikana...
...Phase II cancer trials of Panzem and MKC-1 , that latter of which came from Miikana...
BioCentury | Jan 30, 2006
Clinical News

MKC-1: Phase II started

...Phase II trial in patients with oral MKC-1. ENMD got MKC-1 through its acquisition of Miikana Therapeutics Inc....
BioCentury | Jan 16, 2006
Company News

EntreMed, Miikana deal

...ENMD completed its previously announced acquisition of Miikana for 10 million shares (see BioCentury, Jan. 2...
...$2.37 on Jan. 12, the day the deal closed, Miikana is valued at $23.7 million. Miikana...
...in milestones, payable in cash or stock at ENMD's option. EntreMed Inc. (ENMD), Rockville, Md. Miikana Therapeutics Inc....
BioCentury | Jan 2, 2006
Company News

EntreMed, Miikana deal

...Cancer and inflammation company ENMD will acquire Miikana for 10 million shares, which values Miikana at...
...using ENMD's close of $2.13 on Dec. 21, the day before the deal was announced. Miikana...
...in cash or stock at ENMD's option. The deal is expected to close this month. Miikana's...
Items per page:
1 - 10 of 24
BioCentury | Feb 18, 2013
Finance

Wanted: Platform plays

...which Affymetrix Inc. (NASDAQ:AFFX) acquired in 2008 for about $73 million; and cancer company Miikana Therapeutics Inc....
BioCentury | May 19, 2008
Clinical News

ENMD-2076: Phase I ongoing

...triggered a $2 million milestone payment, paid in EntreMed stock to the former shareholders of Miikana...
BioCentury | Apr 14, 2008
Clinical News

ENMD-2076: Phase I started

...a $2 million milestone payment payable in cash or stock to the former stockholders of Miikana...
BioCentury | Sep 17, 2007
Clinical News

MKC-1: Interim Phase II data

...recommended continuation of the study without any modifications. ENMD gained MKC-1 through its acquisition of Miikana Therapeutics Inc....
BioCentury | Sep 11, 2007
Clinical News

EntreMed reports Phase II breast cancer data

...study without any modifications. ENMD gained the oral cell cycle inhibitor through its acquisition of Miikana...
BioCentury | Jan 29, 2007
Clinical News

MKC-1: Phase II ongoing

...to 60 patients advanced or metastatic breast cancer. ENMD gained MKC-1 through its acquisition of Miikana Therapeutics Inc....
BioCentury | Feb 6, 2006
Finance

Ebb & Flow

...seek FDA approval for their products this year. Buy & raise When EntreMed (ENMD) acquired Miikana...
...with most of the proceeds earmarked for clinical development. "Between our own pipeline and the Miikana...
...Phase II cancer trials of Panzem and MKC-1 , that latter of which came from Miikana...
BioCentury | Jan 30, 2006
Clinical News

MKC-1: Phase II started

...Phase II trial in patients with oral MKC-1. ENMD got MKC-1 through its acquisition of Miikana Therapeutics Inc....
BioCentury | Jan 16, 2006
Company News

EntreMed, Miikana deal

...ENMD completed its previously announced acquisition of Miikana for 10 million shares (see BioCentury, Jan. 2...
...$2.37 on Jan. 12, the day the deal closed, Miikana is valued at $23.7 million. Miikana...
...in milestones, payable in cash or stock at ENMD's option. EntreMed Inc. (ENMD), Rockville, Md. Miikana Therapeutics Inc....
BioCentury | Jan 2, 2006
Company News

EntreMed, Miikana deal

...Cancer and inflammation company ENMD will acquire Miikana for 10 million shares, which values Miikana at...
...using ENMD's close of $2.13 on Dec. 21, the day before the deal was announced. Miikana...
...in cash or stock at ENMD's option. The deal is expected to close this month. Miikana's...
Items per page:
1 - 10 of 24